Soleno Therapeutics, Inc. (SLNO) |
|
2.81 0.22 (8.49%)
|
01-27 16:00 |
|
Open: |
2.6 |
Pre. Close: |
2.59 |
|
High:
|
2.84 |
Low:
|
2.58 |
|
Volume:
|
110,083 |
Market Cap:
|
23(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:00 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.67 One year: 4.29 |
| Support: |
Support1: 2 Support2: 1.29 |
| Resistance: |
Resistance1: 3.15 Resistance2: 3.67 |
| Pivot: |
2.38  |
| Moving Average: |
MA(5): 2.51 MA(20): 2.32
MA(100): 1.57 MA(250): 2.55  |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 65.5 %D(3): 63.8 |
| RSI: |
RSI(14): 69.5 |
| 52-week: |
High: 6.3 Low: 0.15 |
| Average Vol(K): |
3-Month: 2,103 (K) 10-Days: 176 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLNO ] has closed above the upper band by 9.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.84 - 2.86 |
2.86 - 2.87 |
|
Low:
|
2.55 - 2.56 |
2.56 - 2.58 |
|
Close:
|
2.79 - 2.81 |
2.81 - 2.83 |
|
Company Description |
|
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. |
Headline News |
Thu, 26 Jan 2023
Soleno Therapeutics (SLNO) Announces Peer-Reviewed ... - StreetInsider.com
Thu, 19 Jan 2023
Is Soleno Therapeutics Inc (SLNO) Stock About to Get Hot Thursday? - InvestorsObserver
Fri, 06 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 03 Jan 2023
Is Soleno Therapeutics Inc (SLNO) a Winner in the Biotechnology Industry? - InvestorsObserver
Tue, 27 Dec 2022
Healthcare Stocks Moving Tuesday: HTGM, ATNF, BDTX, SLNO, ACER, COSM, PIII, HLTH - InvestorsObserver
Tue, 20 Dec 2022
Should You Hold Soleno Therapeutics Inc (SLNO) Stock Tuesday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
14.9 (%) |
|
% Held by Institutions
|
38.4 (%) |
|
Shares Short
|
99 (K) |
|
Shares Short P.Month
|
52 (K) |
Stock Financials |
|
EPS
|
-0.35 |
|
EPS Est Next Qtl
|
-0.25 |
|
EPS Est This Year
|
-1.36 |
|
EPS Est Next Year
|
-1.05 |
|
Book Value (p.s.)
|
1.86 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-42.3 |
|
Return on Equity (ttm)
|
-121 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.86 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-23 (M) |
|
Levered Free Cash Flow
|
-13 (M) |
Stock Valuations |
|
PE Ratio
|
-8.1 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1.51 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-10-05 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
